These results suggested that SIRT1 suppresses p66shc expression during NAFLD and that activation of the SIRT1/p66shc pathway is involved in the hepatoprotective effect of CA in NAFLD. The gene discussed is SIRT1; the disease is metabolic dysfunction-associated steatotic liver disease.